首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

2050744

修美樂生物相似藥市場：依產品類型、適應症、銷售管道、病患年齡及地區分類

Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography

出版日期: 2026年03月26日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，阿達木單抗生物相似藥市場規模將達到 19.426 億美元，到 2033 年將達到 98.488 億美元。預計從 2026 年到 2033 年，該市場將以 26.1% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	19.426億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	26.10%	2033年市場規模預測：	98.488億美元

阿達木單抗（Humira）是一種用於治療乾癬和類風濕性關節炎等自體免疫疾病的生物製藥，也是全球使用最廣泛的生物製藥。隨著阿達木單抗在部分地區的專利保護到期，生物相似藥應運而生。生物相似藥是學名藥，在安全性、療效和品質方面與生物製藥高度相似。這些生物相似藥促進了市場競爭，並可能降低價格。透過提供更經濟的治療方案，它們有助於降低醫療成本，並提高患者獲得基本藥物的機會。生物相似藥已證實與原廠生物製藥具有相當的療效和安全性，使其成為銀屑病和類風濕性關節炎等疾病患者的可行替代方案。此外，生物相似藥的普及刺激了製藥業的創新，鼓勵生產商在不降低品質的前提下開發更經濟實惠的治療方案。這種市場競爭最終會降低價格，提高病患的用藥可近性，進而改善醫療保健效果。此外，生物相似藥的引入也增加了患者的選擇權和自主權，使患者能夠選擇最經濟有效的、最適合其特定需求的治療方法。

市場動態

專利到期、成本降低、自體免疫疾病的日益普遍以及有利的法規環境是預計在預測期內推動全球阿達木單抗生物相似藥市場成長的關鍵因素。

例如，北美地區已核准並上市了多種阿達木單抗（Humira）生物相似藥，該地區在生物相似藥的引進方面發揮了先鋒作用。由於該地區現有的法律體制和政策支持生物相似藥的引進，預計市場競爭將進一步加劇，成本降低的潛力也將隨之增加。

然而，複雜的監管流程、圍繞智慧財產權和專利的訴訟，以及醫生和患者缺乏相關意識，預計將在預測期內阻礙全球腦血管血管造影術市場的成長。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
本研究根據以下參數分析了全球 Humira 生物相似藥市場的主要參與者：公司亮點、產品系列、主要特徵、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球阿達木單抗生物相似藥市場報告面向產業內的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球阿達木單抗生物相似藥市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

公司簡介
- Amgen Inc.
- Samsung Bioepis Co.
- Sandoz International GmbH（Novartis AG）
- Mylan NV
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co.
- Viatris Inc.
- Alvotech
- Analysts'Views

第10章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI5925

Humira Biosimilar Market is estimated to be valued at USD 1,942.6 Mn in 2026 and is expected to reach USD 9,848.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 26.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,942.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	26.10%	2033 Value Projection:	USD 9,848.8 Mn

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market.

Market Segmentation

By Product Type (Revenue, USD Mn, 2021 - 2033)
Biosimilar Humira (Adalimumab)
Interchangeable Biosimilar Humira
By Indication (Revenue, USD Mn, 2021 - 2033)
Rheumatoid Arthritis
Psoriasis
Crohn's Disease
Ulcerative Colitis
Ankylosing Spondylitis
Juvenile Idiopathic Arthritis
Other Autoimmune Conditions
By Patient Age (Revenue, USD Mn, 2021 - 2033)
Adult Patients
Pediatric Patients
Geriatric Patients
By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top companies in Global Humira Biosimilar Market
Amgen
Samsung Bioepis Co., Ltd.
Sandoz International GmbH (Novartis AG)
Mylan N.V.
Boehringer Ingelheim International GmbH
Pfizer Inc.
Fresenius Kabi AG
Coherus BioSciences, Inc.
Biogen Inc.
AbbVie Inc.
Celltrion Inc.
Rani Therapeutics Holdings, Inc.
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Viatris Inc.
Alvotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market, By Product Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Humira Biosimilar Market, By Indication, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Humira Biosimilar Market, By Patient Age, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Humira Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

8. Global Humira Biosimilar Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2021 - 2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Samsung Bioepis Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sandoz International GmbH (Novartis AG)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Fresenius Kabi AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Coherus BioSciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Celltrion Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Rani Therapeutics Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alvotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analysts' Views